Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181848 | 0.78 | KCNH2 (0.84) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL20181508 | 0.78 | KCNH2 (0.73) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL20163024 | 0.77 | HDAC3 (0.59) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL20163148 | 0.76 | HDAC3 (0.57) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL20176404 | 0.76 | KCNH2 (1.00) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL23960955 | 0.74 | HDAC3 (0.59) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL12535767 | 0.74 | HDAC1 (0.47) | HDAC3HDAC2MEN1ALDH1A1KMT2A | |
| SCHEMBL13833383 | 0.73 | HDAC1 (0.70) | HDAC3HDAC2HDAC1 | |
| SCHEMBL20181696 | 0.73 | HDAC3 (0.72) | KCNH2HDAC3HDAC2HDAC1 | |
| SCHEMBL20181695 | 0.73 | HDAC3 (0.57) | KCNH2HDAC3HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | KCNH2 4371/4885HDAC3 6/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.